Celcuity ( (CELC) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celcuity Inc. shares are climbing after the company reported positive topline data from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 trial, showing that its lead drug candidate, gedatolisib, met the primary goal of improving progression-free survival in breast cancer patients. The move appears driven by company-specific news, as investors bet on the drug’s regulatory and commercial potential.
Analyst sentiment has turned more bullish in response to the trial success, with Citizens recently reiterating its optimism and setting a price target of $150 for Celcuity stock. That target underscores growing expectations that the FDA will accept a planned supplemental New Drug Application and eventually clear gedatolisib for market.
More about Celcuity
YTD Price Performance: 25.98%
Average Trading Volume: 746,223
Technical Sentiment Signal: Buy
Current Market Cap: $5.87B
For further insights into CELC stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.